Home/Filings/4/0001838139-25-000012
4//SEC Filing

Urist Marshall 4

Accession 0001838139-25-000012

CIK 0001802768other

Filed

Dec 21, 7:00 PM ET

Accepted

Dec 22, 4:09 PM ET

Size

7.1 KB

Accession

0001838139-25-000012

Insider Transaction Report

Form 4
Period: 2025-12-19
Urist Marshall
EVP, Research & Investments
Transactions
  • Sale

    Class A Ordinary Shares

    2025-12-19$38.38/sh20,000$767,582120,000 total(indirect: By LLC)
Holdings
  • Class A Ordinary Shares

    (indirect: By IRA)
    19,020
  • Class A Ordinary Shares

    7,398
Footnotes (2)
  • [F1]All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on September 16, 2025.
  • [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.22 to $38.57 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Issuer

Royalty Pharma plc

CIK 0001802768

Entity typeother

Related Parties

1
  • filerCIK 0001838139

Filing Metadata

Form type
4
Filed
Dec 21, 7:00 PM ET
Accepted
Dec 22, 4:09 PM ET
Size
7.1 KB